Abiraterone Acetate 500 mg
| Product Overview | |
| Generic Name | Abiraterone Acetate 500 mg |
| Brand Name(s) | ZYTIGA® |
| Product Type | Generic |
| Form | 60 Oral Tablets, plastic bottle |
| Strength | 500 mg |
| Therapeutic Class | Cancer, Hormone antagonists and related agents |
| ATC Code | L02BX03 |
| Manufacturing & Regulatory | |
| Manufacturer | Janssen Biotech |
| Country | Italy, India, Canada, USA |
| GMP Compliance | W.H.O. |
| DMF/CEP | Type II: API DMFs |
| COFEPRIS | 010.000.6211.00 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 bottles |
| Shelf Life | 24 Months |
| Storage | Controlled room temperature 20–25 °C |
| Incoterms | Ex-Works, 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | Upon Request |
Description
Indications & Usage: Treats prostate cancer advanced metastatic.
Description: INN: Abiraterone Acetate
- Strength: 500 mg
- Dosage Form: Tablet
- Presentation: Box of 60 tablets
- CNIS/Clave: 010.000.6211.00
- Product Type: Generic procurement presentation
- Therapeutic Class: Androgen Biosynthesis Inhibitor (CYP17 inhibitor)
- ATC Code: L02BX03
